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Objective: Low-dose transdermal opioids offer a new therapeutic option for osteoarthritis (OA). This
study compared symptom relief obtained with buprenorphine patches plus oral paracetamol with that
obtained with an oral codeine-paracetamol combination tablet (co-codamol) in older adults with OA.
Method: Two hundred and twenty people (aged 60 years) with OA hip and/or knee pain were rando-
mised to treatment with 7-day buprenorphine patches plus oral paracetamol (5e25 mg/h buprenorphine
patches plus 1000 mg oral paracetamol q.i.d. (4 times daily); n¼ 110) or co-codamol tablets (two 8/500
etwo 30/500 mg tablets q.i.d.; n¼ 110). They entered a titration period of up to 10 weeks, during which
their dose of study medication was adjusted until they reached optimum pain control. Patients who
achieved optimum pain control entered a 12-week assessment period. The primary outcome was average
daily pain scores recorded using the box scale-11 (BS-11) pain scale.
Results: Both treatments signiﬁcantly reduced patient pain scores. The estimated treatment difference
[95% conﬁdence interval (CI)] was 0.02 (0.64, 0.60) for the per protocol (PP) population. The results
were similar for the full analysis population. Patients receiving 7-day buprenorphine patches plus oral
paracetamol needed signiﬁcantly less escape medication (ibuprofen) than those receiving co-codamol
tablets (P¼ 0.002; PP population). Less than 10% of patients in the 7-day buprenorphine patches plus
oral paracetamol group were receiving the highest dose level at the end of the study, compared with 34%
in the co-codamol group. Withdrawal rates were high in both groups. The incidence of adverse events
(AEs) was comparable between the groups (86.4% of patients in the 7-day buprenorphine patches plus
oral paracetamol group; 81.7% in the co-codamol group). Six serious AEs were reported in three patients
(2.7%) in the 7-day buprenorphine patches plus oral paracetamol group and one (0.9%) in the co-codamol
group.
Conclusions: 7-day buprenorphine patches plus oral paracetamol were non-inferior to co-codamol tablets
with respect to analgesic efﬁcacy in older adults with OA pain in the hip/knee.
Clintrials.gov number: NCT00324038.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is increasingly common and results in
reduced quality of life1. Modern recommendations for the treat-




s Research Society International. Pa combination of pharmacological and non-pharmacological
treatments2e4.
The appropriate prescribing of analgesics in the older personwith
OA is difﬁcult: polypharmacy, co-morbid conditions and poor
compliance occurmore frequently in this group. Research has shown
that 50% of these patients may be taking nine or more medicines for
other conditions when initiated on analgesia for OA5.
First-line therapy is recommended with those agents with the
best tolerability proﬁles, such as paracetamol and topical non-
steroidal anti-inﬂammatory drugs (NSAIDs)2,4. Despite their
increased risks in older patients, NSAIDs are commonly used1.ublished by Elsevier Ltd. All rights reserved.
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inhibitors are associated with a range of adverse events (AEs)6e9
and recent problems have resulted in an increased focus on alter-
native analgesic options.
Recent meta-analyses have assessed the efﬁcacy of opioids for
the treatment of OA and chronic non-malignant pain10e12. These
meta-analyses conﬁrm that opioids provide some beneﬁt in treat-
ing OA pain, however patient selection is important. The most
recent reviews concluded that non-tramadol opioids should not be
used routinely as the beneﬁts are outweighed by the risks11. An
earlier Cochrane review13 examined tramadol in OA pain. The
authors concluded that while tramadol demonstrated improve-
ments in OA pain and function, its use was also associated with AEs
that may cause patients to discontinue treatment.
Oral agents such as tramadol, codeine and dihydrocodeine
(sometimes in combination with paracetamol) are commonly used
to treat OA pain in older patients. However, around 7e10% of
Europeans lack the hepatic CYP 2D6 enzyme to metabolise codeine
into its active form; therefore, these patients get no analgesia from
codeine14. Transdermal preparations of opioids are now available
(buprenorphine and fentanyl), but there is limited information on
their place in the OA armamentarium. Buprenorphine patches are
available in three low-dose strengths, equivalent to daily doses of
codeine and tramadol, which provide continuous delivery of
buprenorphine over a 7-day period. Such background analgesia
may improve patient compliance by reducing the pill burden.
This study compared analgesia obtained with 7-day buprenor-
phine patches plus oral paracetamol with the UK’s most commonly
used paracetamolecodeine combination (co-codamol tablets) in
older people with OA of the hip and/or knee. The study was
designed to reﬂect clinical practice.
Methods
This was an open label, randomised, parallel group study carried
out in 38 predominantly primary care centres across the UK
between September 2006 and August 2007. The study was
approved by central and local research ethics committees and
performed according to the Declaration of Helsinki, 1964. All
patients gave written informed consent.
To enter the study, patients had to be 60-years-old with
clinician-diagnosed knee and/or hip OA (site, duration and severity
of OAwere not recorded), causing severe pain [deﬁned as a score of
5 on the box scale-11 (BS-11) pain scale, where 0¼ no pain and
10¼ pain as bad as you can imagine]. They also had to be taking
their maximum tolerated dose of paracetamol (four or moreTable I
Dose levels of study medication
Dose level 7-day buprenorphine patches plus oral paracetamol
1 5 mg/h (one 5 mg/h patch)
Two 500 mg paracetamol tablets four times a day
2 10 mg/h (one 10 mg/h patch)
Two 500 mg paracetamol tablets four times a day
3 15 mg/h (one 5 mg/h patch plus one 10 mg/h patch)
Two 500 mg paracetamol tablets four times a day
4 20 mg/h (one 20 mg/h patch)
Two 500 mg paracetamol tablets four times a day
5 25 mg/h (one 5 mg/h patch plus one 20 mg/h patch)
Two 500 mg paracetamol tablets four times a day
The doses of codeine used were chosen to be equivalent to the doses of buprenorphine p
midpoint of conversion ratios found in the literature, which vary from 3.3:1 to 10:1, dep
* Codeine phosphate 8 mg, paracetamol 500 mg.
y Codeine phosphate 15 mg, paracetamol 500 mg.
z Codeine phosphate 30 mg, paracetamol 500 mg.500 mg tablets) each day. The original inclusion criteria included
patients65-years-old taking 6e8 500 mg paracetamol tablets per
day. These were changed to improve recruitment. Exclusion criteria
included: painful disease of the joints, other than OA; painful
conditions, other than OA, that were likely towarrant regular use of
rescue analgesics; major elective surgery during the study period;
use of intra-articular steroid injection during the study or in the
6 weeks beforehand; and current use of COX-2 inhibitors.
After giving their consent and undergoing screening, patients
were randomised 1:1 to treatment with 7-day buprenorphine
patches (plus oral paracetamol) or co-codamol tablets according to
a randomisation schedule, stratiﬁed by centre. The randomisation
schedule was prepared by the sponsor, and kept locked on site after
approval by a sponsor statistician. Sealed randomisation envelopes
were provided to each centre, and opened by the investigator in the
presence of each subject at the time of randomisation. The subject
was asked to record the time the envelope was opened, and sign
and date next to this information. As this was an open-label study,
the consent form discussed the two types of treatment available,
and explained that either of the treatments may help with the
patients’ pain.
Patients taking 7-day buprenorphine patches were given
application instructions in line with the patient information leaﬂet.
Patches were applied according to the licence, to the upper outer
arm, upper chest, upper back or the side of the chest, and rotated so
that a new patch was not applied to the same site for 3e4 weeks.
Patients were also provided with a prophylactic dose of a cen-
trally-acting anti-emetic (prochlorperazine), which the investiga-
tors asked them to take three times a day during the ﬁrst week of
the titration period and on an as-needed basis thereafter. Patients
who were receiving a laxative at study entry could continue with
this, and investigators were advised to prescribe a laxative to any
patient who experienced constipation during the study. Patients
could take up to three doses per day of the oral NSAID, ibuprofen
(one dose¼ 400 mg), for breakthrough pain. They were also
advised to take one dose of omeprazole (20 mg) on each day that
they took escape medication. Table I shows the dose levels of study
medication.
Patients entered a titration period of up to 10 weeks, during
which their dose was adjusted every 7 or 14 days, as necessary, to
achieve optimum pain control (sufﬁcient pain control with
minimal side effects). Investigators assessed optimum pain control
by reviewing the escape medication use, pain scores and AEs.
Patients who achieved optimum pain control entered the assess-
ment period, which lasted for 12 weeks. The investigator could
adjust the patient’s dose of study medication, if necessary, afterCo-codamol tablets
Two 8/500 mg tablets* four times a day
One 8/500 mg tablets plus one 15/500 mg tablety four times a day
Two 15/500 mg tablets four times a day
Two 15/500 mg tablets four times a day
Two 30/500 mg tabletsz four times a day
atches. For codeine, a conversion ratio of 6:1 vs morphine has been used. This is the
ending on the model used15,16.
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visit was conducted 4 weeks after completion or discontinuation
from the study.
Primary measures
The primary efﬁcacy measure was the average daily BS-11 pain
score that patients recorded each evening before going to bed. The
patients were asked, “Overall, what has your pain been like today?
Please circle the number which indicates your average pain over
the past 24 h.” Although the diary was checked at each weekly visit,
therewas no formal veriﬁcation of the time it was completed by the
patient.
Secondary measures
Patients were asked to record the number of ibuprofen tablets
(escape medication) that they took each day. They also recorded
laxative use. At entry to and completion of (or discontinuation
from) the study, patients recorded several sleep parameters [sleep
disturbance, snoring, shortness of breath, headache, sleep
adequacy and optimal sleep dichotomy (i.e., whether they slept for
7e8 h)] based on the Medical Outcomes Study (MOS) Sleep Scale.
The optimum method of titration was assessed by looking at time
to achieve stable pain control, length of time on anti-emetics and
discontinuation of patients during the titration period.
Exploratory measures
At screening, the end of the titration period and completion of
(or discontinuation from) the study, the investigators assessed
patients’ pain, stiffness and ability to perform daily activities,
separately and as a total score, using the Western Ontario and
McMaster Universities (WOMAC) OA Index (Version VA3.1). At
completion of (or discontinuation from) the study, investigators
assessed patients’ satisfaction with treatment using the Treatment
Satisfaction Questionnaire for Medication (TSQM). The investiga-
tors assessed the patients’ quality of life using the EuroQol EQ-5D
(EQ-5D) and the General Well-being Index at screening, at
various points during the assessment period, and at completion of
(or discontinuation from) the study. They also assessed patch
durability at each visit during the titration and assessment periods.
Each week, patients recorded whether they had used additional
healthcare resources.
Full analysis of sleep scores, WOMAC scores and time to
optimum pain control was not planned to avoid multiplicity issues.
For these endpoints, only summary statistics were planned.
Safety assessments
At each study visit, the investigator recorded any AEs that the
patients volunteered. At baseline, patients in the 7-day buprenor-
phine patch group assessed potential patch application sites for
itchiness, and the investigators assessed them for erythema and
oedema. Patients also assessed the patch application site for
redness, itchiness, and swelling at 0, 12, and 24 h after removal of
each patch. After removal of the ﬁnal patch, the investigator
assessed the site for erythema and oedema.
Statistical analyses
It was estimated that, with 50 completing patients in each
treatment group, the study would have 90% power at the 5%
signiﬁcance level to conﬁrm that 7-day buprenorphine patches are
non-inferior to co-codamol. Non-inferiority was to be assumed ifthe lower 95% CI for the estimated treatment difference was 1.5
boxes on the BS-11 scale, this was based on the assumption that the
mean pain score for both treatments was the same and that the
pooled standard deviation (SD) was 2.25 boxes. As the study was
a non-inferiority trial, the per protocol (PP) population was the
primary population for the efﬁcacy end-point as this is more
conservative and as a result the study was conducted at 90% power.
The efﬁcacy datawere analysed using the full analysis population to
provide conﬁrmation. For the summary and analysis of the mean
BS-11 score in the full analysis population, missing data were
imputed using the last observation carried forwards (LOCF).
The full analysis population included those patients who
received at least one dose of study medication and had at least one
primary efﬁcacy measurement after randomisation. In this study,
therewas no difference between the intent-to-treat population and
the full analysis population, as patients excluded for not having
a post-randomisation efﬁcacy measurement would not have had
any data to contribute to the analysis had they been included. The
term full analysis population has been used to be consistent with
the ICH guideline on statistical principles (ICHE9). The PP pop-
ulation included patients who were in the full analysis population,
but had no major protocol violations and completed at least 75% of
the assessment period. The safety population included those
patients who received at least one dose of study medication and
had at least one safety measurement after randomisation. As this
was a non-inferiority study, we considered the PP population to be
the primary population of interest. Therefore, primary and
secondary efﬁcacy data are presented for both the PP and full
analysis populations, demographic and exploratory efﬁcacy data
are presented for the full analysis population, and safety data are
presented for the safety population.
Mean BS-11 pain scores and escape medication use were ana-
lysed using a repeated measures analysis of covariance. For the
analysis of pain scores, baseline scores and centre were included as
covariates; centre was a covariate for the analysis of escape medi-
cation use.
Results
Figure 1 shows the ﬂow of patients through the study. The PP
population included 117 patients: 61 in the 7-day buprenorphine
patch plus oral paracetamol group and 56 in the co-codamol tablets
group. The full analysis population included 209 patients: 107 in
the 7-day buprenorphine patch plus oral paracetamol group and
102 in the co-codamol tablets group. Their demographic data are
shown in Table II.
Forty-nine patients (45%) in the 7-day buprenorphine patch plus
oral paracetamol group and 52 (47%) in the co-codamol tablets
group withdrew from the study. Of these, 38 (78%) in the 7-day
buprenorphine patch plus oral paracetamol group and 24 (46%) in
the co-codamol tablets group withdrew because of AEs. Only ﬁve
patients (10%) in the 7-day buprenorphine patch plus oral para-
cetamol group withdrew because of lack of therapeutic effect,
compared with 13 (25%) in the co-codamol tablets group. In both
groups, similar numbers of patients who withdrew from the study
did so during the titration period [43 (88%) in the 7-day bupre-
norphine patch plus oral paracetamol group and 46 (88%) in the co-
codamol tablets group]. There was no planned analysis to look at
differences between the patients who completed and those who
withdrew from the study.
Efﬁcacy
Table III shows patients’ mean BS-11 pain scores at baseline, the
end of the titration period and during the assessment period. The
Fig. 1. Flow of patients through the study.
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Table II
Patient demographics
7-day buprenorphine patch plus





Age (years)* 71.8 (58,90) 71.1 (60,87) 71.4 (58,90)
Sexy
Male/Female 37 (34)/73 (66) 38 (35)/72 (65) 75 (34)/145 (66)
Racey
Caucasian 107 (97) 109 (99) 216 (98)
Black 0 (0) 1 (1) 1 (<1)
Asian 3 (3) 0 (0) 3 (1)
Details of medical history, current medical conditions and co-medications were collected but have not been reported here.
* Mean (range).
y Number (%) of patients.
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the end of the titration period (a decrease of two boxes or more is
considered to be clinically relevant17). This improvement was
maintained throughout the assessment period. Analysis of the pain
scores for the PP population at 2-weekly intervals during the
assessment period gave an estimated treatment difference [95%
conﬁdence interval (CI)] of 0.02 (0.64, 0.60). For the full analysis
population, the estimated treatment difference (95% CI) was 0.07
(0.67, 0.54). The lower limits of these CIs were above the pre-
deﬁned limit of 1.5 boxes, demonstrating that the 7-day bupre-
norphine patches are non-inferior to co-codamol tablets.
In the PP population, patients receiving 7-day buprenorphine
patches plus oral paracetamol required approximately one
dose (33%) less per day of escape medication (ibuprofen) than
those receiving co-codamol tablets. The estimated treatment
difference (95% CI) was 0.98 (1.55, 0.40); P¼ 0.002. Results
were similar for the full analysis population.
By the end of the study, eight patients (7%) in the buprenorphine
patch plus oral paracetamol group were receiving the highest
allowed dose level of study medication (25 mg/h), compared
with 35 patients (34%) who were receiving the highest dose of
co-codamol tablets (two 30/500 mg tablets four times a day).
Results from theMOS Sleep Scale showed that sleep disturbance
decreased during the study in both treatment groups in the PP and
full analysis populations (Table IV). Mean (SD) sleep disturbance
scores dropped from 33.9 (22.09) at baseline to 24.3 (25.32) at
study completion (or discontinuation) in the group receiving
buprenorphine patches plus oral paracetamol. Mean sleep distur-
bance scores dropped from 41.8 (28.60) at baseline to 32.9 (26.10)
at study completion (or discontinuation) in the group receiving
co-codamol tablets. Both groups reported increased sleep
adequacy; in the PP population, this improvement was more
marked in the 7-day buprenorphine patch plus oral paracetamol
group where mean sleep adequacy score rose from 50.8 (25.35) at
baseline to 62.5 (28.26) at the end of the study. Patients receiving
co-codamol tablets reported mean sleep adequacy scores of 56.1Table III
BS-11 pain scores at baseline, end of titration and during the assessment period
BS-11 pain scores (boxes) mean (SD)
PP population
7-day buprenorphine patch plus
oral paracetamol (n¼ 61)
Baseline 7.0 (1.31)
End of titration 3.4 (1.44)
Assessment period Weeks 1 and 2 2.9 (1.71)
Weeks 3 and 4 3.0 (1.80)
Weeks 5 and 6 2.9 (1.65)
Weeks 7 and 8 2.9 (1.74)
Weeks 9 and 10 2.8 (1.71)
Weeks 11 and 12 3.0 (1.85)
* Except for Weeks 11 and 12 of the assessment period (n¼ 54).(25.84) at baseline and 59.1 (26.41) at the end of the study. There
was no clinical treatment difference in the number of hours slept,
although there was a slight increase in the number of patients with
optimal sleep in the 7-day buprenorphine patch plus oral para-
cetamol group, compared with a slight decrease in the co-codamol
tablets group. Patients receiving the 7-day buprenorphine patch
plus oral paracetamol reported no change in their snoring scores,
while those receiving co-codamol tablets reported a slight
improvement. Neither treatment had any effect on shortness of
breath or headache. In the PP population, neither treatment had
any effect on somnolence, but in the full analysis population, there
was a slight increase in somnolence scores in both treatment
groups between baseline and the end of the study.
Fifty percent of patients in each treatment group did not require
laxatives during the study. When laxatives were used, they were
required for slightly less time by patients in the 7-day buprenor-
phine patch plus oral paracetamol group than by those in the co-
codamol tablet group. The median (interquartile range)
percentage of days on which laxatives were used was 0 (0e6.1) in
the 7-day buprenorphine patch plus oral paracetamol group and
0 (0e6.9) in the co-codamol tablets group (PP population). Results
were similar for the full analysis population.
During the titrationperiod, anti-emetic usewas slightly higher in
the 7-day buprenorphine patch plus oral paracetamol group than in
the co-codamol tablets group: the median (interquartile range)
percentage of days on which anti-emetics were used was 18.5
(0e70.6) and0 (0e26.8), respectively (PPpopulation). However, this
decreased markedly in the 7-day buprenorphine patch plus oral
paracetamol group during the assessment period to 0 (0e13.3)
percent of dayswith anti-emetic use. Thiswas comparable to the co-
codamol group. Results were similar for the full analysis population.
During titration, the mean (SD) time to optimum pain control
was 19.5 (11.5) days for patients receiving the 7-day buprenorphine
patch plus oral paracetamol, compared with 21.8 (13.76) days for
those receiving co-codamol tablets. The median values (i.e., the




plus oral paracetamol (n¼ 107)
Co-codamol tablets
(n¼ 102)
7.0 (1.11) 7.0 (1.29) 7.0 (1.27)
3.7 (1.66) 4.3 (1.94) 4.4 (2.12)
3.2 (2.00) 4.0 (2.21) 4.1 (2.45)
3.0 (2.02) 4.0 (2.27) 4.0 (2.54)
2.9 (1.99) 4.0 (2.21) 4.0 (2.56)
2.9 (1.96) 4.0 (2.27) 4.0 (2.55)
3.0 (1.99) 4.0 (2.26) 4.1 (2.53)
3.0 (2.12) 4.0 (2.29) 4.2 (2.61)
Table IV
MOS Sleep Scales e sleep disturbance: PP population
7-day buprenorphine patch plus oral paracetamol Co-codamol tablets
Baseline Completion/discontinuation Baseline Completion/discontinuation
N 60 60 56 56
Mean (SD) 33.9 (22.09) 24.3 (25.32) 41.8 (28.60) 32.9 (26.10)
Minimum, maximum 0, 90 0, 100 0, 95 0, 100
Lower quartile 18.1 5.6 17.5 11.3
Median 31.3 15.6 32.5 27.5
Upper quartile 48.8 31.3 70.0 47.5
Table VI
Skin reactions at the end of the study and at the outcome visit
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and 20.5 days in the co-codamol tablet group. The results showed
no clear relationship for either treatment between the speed of
initial up-titration and AEs, discontinuation rates, or use of an anti-
emetic. It was noted from the medications returned that many
patients did not take their anti-emetic, breakthrough analgesia
(ibuprofen) or proton pump inhibitor (omeprazole).
In both treatment groups, patients’ total scores on the WOMAC
OA Index improved during the study. At baseline, patients’ mean
(SD) scores were 174.2 (52.71) in the 7-day buprenorphine patch
plus oral paracetamol group and 184.1 (50.31) in the co-codamol
group. By the end of the titration period, these had decreased to
85.5 (53.81) and 104.8 (50.31), respectively. At the end of the
assessment period, the scores were 130.9 (73.91) in the 7-day
buprenorphine patch plus oral paracetamol group and 141.2 (71.05)
in the co-codamol tablets group.
Patients’ scores for effectiveness of treatment and satisfaction
with treatment were similar in the two treatment groups. Patients
receiving the 7-day buprenorphine patch plus oral paracetamol
recorded lower (i.e., better) scores for side effects than those
receiving co-codamol tablets, but their scores for convenience of
using the medication were higher (possibly as a result of having to
take eight additional oral paracetamol tablets each day).
Results from the General Well-being Index and the EQ-5D
showed little difference between treatment groups with respect
to quality of life. However, a post-hoc analysis of the EQ-5D results
showed that patients in both groups had a mean increase in utility
scores from baseline of 0.2.
Nomore than eight patients reported any of the patch durability
issues during the study. Most patches stayed in place for the full 7
days of wear.
Very few patients in either group used additional healthcare
resources between study visits. This is likely to be because they
already had signiﬁcant contact with healthcare professionals as
a result of being in the study.
Safety
The safety population included 219 patients: 110 in the 7-day
buprenorphine patch plus oral paracetamol group and 109 in theTable V
Most commonly reported AEs
Number (%) of patients
7-day buprenorphine patch plus
oral paracetamol (n¼ 110)
Co-codamol tablets
(n¼ 109)
Constipation 28 (26) 35 (32)
Nausea 44 (40) 27 (25)
Vomiting 12 (11) 9 (8)
Erythema at
application site
30 (27) 0 (0)
Pruritus at
application site
19 (17) 0 (0)
Dizziness 15 (14) 6 (6)co-codamol group. Table V shows the most common treatment-
emergent AEs (i.e., those that were reported by 10% of patients
in either treatment group). Overall, 95 patients (86%) in the 7-day
buprenorphine patch plus oral paracetamol group and 89 (82%) in
the co-codamol tablets group reported treatment-emergent AEs.
Most of the AEs were mild or moderate in intensity. Thirty patients
(27%) in the 7-day buprenorphine patch plus oral paracetamol
group reported erythema at the patch application site at some
point during the study; 19 (17%) reported pruritus.
A total of six serious AEs (serious adverse events (SAEs); deﬁned
according to Food and Drug Administration (FDA) guidance18) were
recorded for three patients (2.7%) in the 7-day buprenorphine
patch plus oral paracetamol group and one (0.9%) in the co-
codamol tablets group. These included chest pain, peripheral
oedema, fall, patella fracture and dyspnoea in the 7-day bupre-
norphine patch plus oral paracetamol group and arthritis in the co-
codamol tablets group.
Table VI shows patients’ assessment of the patch application site
at completion of, or discontinuation from, the study, and at the
outcome visit. Less than 10% of patients reported moderate or
severe reactions; the investigators’ assessments were similar.
Severe skin reactions occurred with less than 1% of patches used in
this study. Mild erythema was reported with 192 patches (18%)
immediately after patch removal. By 24 h after removal, this had
decreased to 87 (8%), indicating that erythema is short-lived.
Table VII shows the AEs that led to discontinuation from the study.Discussion
This is the ﬁrst report of a head-to-head, active comparator
randomised trial between low-dose 7-day buprenorphine patches
and an oral codeine-paracetamol combination in older adults withNone 78 (71) 95 (89)
Mild 22 (20) 10 (9)
Moderate 6 (5) 0 (0)
Severe 2 (2) 0 (0)
Itchiness:
None 88 (80) 98 (92)
Mild 16 (15) 7 (6)
Moderate 2 (2) 0 (0)
Severe 2 (2) 0 (0)
Swelling:
None 104 (95) 105 (98)
Mild 5 (1) 0 (0)
Moderate 2 (2) 0 (0)
Severe 1 (1) 0 (0)
For each measurement there were two patients (2%) in each group with missing
data.
Table VII
Treatment-emergent AEs that led to discontinuation from the study







Abdominal pain 1 (0.9%)
Abdominal pain e upper 1 (0.9%)
Constipation 6 (5.5%) 8 (7.3%)
Diarrhoea 2 (1.8%) 1 (0.9%)
Dry mouth 1 (0.9%) 3 (2.8%)
Nausea 17 (15.5%) 6 (5.5%)
Rectal Haemorrhage 1 (0.9%)
Vomiting 9 (8.2%) 1 (0.9%)
General disorders and administration site conditions
Application site erythema 3 (2.7%)
Application site oedema 1 (0.9%)
Application site pruritus 2 (1.8%)
Fatigue 2 (1.8%)
Malaise 2 (1.8%)
Non-cardiac chest pain 1 (0.9%)







Anorexia 2 (1.8%) 1 (0.9%)
Musculoskeletal and connective tissue disorders
Arthralgia 2 (1.8%)
Arthritis 1 (0.9%)
Back pain 1 (0.9%)
Joint swelling 1 (0.9%)
Muscle spasms 1 (0.9%) 1 (0.9%)
OA 1 (0.9%)
Nervous system disorders
Dizziness 5 (4.5%) 2 (1.8%)
Headache 2 (1.8%) 1 (0.9%)
Lethargy 4 (3.7%)
Paraesthesia 1 (0.9%)
Somnolence 5 (4.5%) 1 (0.9%)
Psychiatric disorders
Anxiety 1 (0.9%)




Reproductive system and breast disorders
Erectile dysfunction 1 (0.9%)
Respiratory, thoracic and mediastinal disorders
Dyspnoea 1 (0.9%)
Renal and urinary disorders
Dysuria 1 (0.9%)
Polyuria 1 (0.9%)
Skin and subcutaneous disorders
Allergic dermatitis 1 (0.9%)
Hyperhidrosis 1 (0.9%)
Pruritus 1 (0.9%)
Facial swelling 1 (0.9%)
Vascular disorders
Deep vein thrombosis 1 (0.9%)
Hot ﬂush 1 (0.9%)
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buprenorphine patches plus oral paracetamol were non-inferior to
co-codamol with respect to efﬁcacy in older adults with OA of the
hip and/or knee. Both treatments gave a clinically signiﬁcant
reduction of more than three boxes in patients’ BS-11 pain scores.
Patients receiving the 7-day buprenorphine patch required signif-
icantly less NSAID (ibuprofen) than those receiving co-codamol
tablets.
At the end of the study, less than 10% of patients receiving the
7-day buprenorphine patch were on the highest dose level,compared with 34% of those receiving co-codamol tablets. This
indicates that low doses of the 7-day buprenorphine patch are
equivalent to low-to-medium doses of codeine (in co-codamol),
and are therefore suitable for patients requiring a low-dose
opioid after paracetamol and topical NSAIDs have failed. All recent
guidelines for OA management (including those from The National
Institute for Health and Clinical Excellence2 and Osteoarthritis
Research Society International4) and a systematic review of
guidelines from 1945 to 20063 supports the appropriate use of
opioids.
Fifty percent of patients receiving the 7-day buprenorphine
patch plus oral paracetamol reached optimum pain control in
2 weeks, compared with almost 3 weeks for those receiving co-
codamol tablets. This demonstrates that titration to pain control
with a long-acting patch can be similar to that with an oral pain
medication taken four times a day.
Although the use of anti-emetics was slightly higher in the
7-day buprenorphine patch plus oral paracetamol group during the
titration period, it decreased markedly during the assessment
period, suggesting that once patients are established on their
optimum dose of buprenorphine, their requirement for anti-
emetics is reduced. We investigated whether use of anti-emetics
during the ﬁrst 7 days of treatment could minimise patient
discontinuations. However, we could not draw any ﬁrm conclusions
as the patient diaries and returned clinical supplies indicated that
many patients did not take their anti-emetics as advised.
Patients’ quality of life improved in both treatment groups. The
results showed an increase in patients’ total WOMAC OA Index
scores between the end of titration and the end of the study.
However, this increase may be due to the inclusion of discontinued
subjects who showed little improvement in their scores; the overall
trend was a reduction in scores. The increase in utility scores from
the EQ-5D represents a signiﬁcant change, which could be due to
the analgesia that patients got from the study medication, or it
could reﬂect the fact that theywere participating in a study. Quality
of life instruments such as EQ-5D do not consider changes in social
circumstances, which may be especially important in the older
person who may be more reliant on family and social services.
In this study, we had a longer than usual titration period to give
patients time to adjust and stabilise their doses. The overall drop-
out rate was high in both treatment groups, but it is not unusual
to see this in opioid trials, owing to side effects and heterogeneity of
opioid responsiveness17,19. The percentage of subjects who dis-
continued due to AEs was higher among subjects who received
buprenorphine patch treatment plus oral paracetamol (77.6%) than
among subjects who received co-codamol treatment (46.2%), this
appears to be mainly due to the differences in nausea levels that
patients experienced. Most patients who withdrew did so during
the titration period. This, combined with the lack of prophylactic
anti-emetic use and breakthrough analgesics during the ﬁrst week
of the study, indicates that more studies are needed to better
understand whether there could be an optimum method of titra-
tion. However, we did show that there appeared to be little rela-
tionship between the speed of initial up-titration and AEs,
discontinuation rates, or use of anti-emetics.
Studies in older populations present signiﬁcant practical
difﬁculties due to co-morbidities, associated polypharmacy,
poor compliance, and reduced cognition (forgetfulness)2022.
Co-medications cannot be discontinued to enter a clinical trial, and
dictate the practicalities of trial design. A double-blind double
dummy placebo controlled RCT may be considered the ‘gold stan-
dard’ for active comparator drug trials, and because we didn’t use
such a design, patients’ assumptions or beliefs about patches and
tablets may have inﬂuenced the results. We chose an open-label
study design because of the difﬁculties that blinding different
P.G. Conaghan et al. / Osteoarthritis and Cartilage 19 (2011) 930e938 937formulations (i.e., patches and tablets) presents. An open design
more closely reﬂected clinical practice and simpliﬁed administra-
tion of the study medication. It was apparent that trial patients
demonstrated lack of compliancewith their use of anti-emetics and
NSAID/proton pump inhibitor (PPI) use for breakthrough analgesia.
Taking analgesic potencies into consideration (as we did when
choosing the dose levels for this study), we would expect similar
pain scores in the two treatment groups; hence the non-inferiority
design.
The results of this study reinforce the ﬁndings of the recent
meta-analyses discussed earlier10e13, that opioid analgesics do have
a role in the management of chronic non-malignant pain. Although
opioids have been associated with increased AEs, they are a useful
option in patients for whom other pain medications such as NSAIDs
are contra indicated.
In conclusion, this is the ﬁrst report demonstrating that 7-day
buprenorphine patches plus oral paracetamol are non-inferior to
a commonly used, oral codeine-paracetamol preparation with
respect to analgesic efﬁcacy in older people with OA pain of the hip
and/or knee. Short-term, minor opioid toxicity occurs with all
modes of delivery, but in patients who are able to tolerate the
treatment, patches offer a convenient and effective alternative
therapeutic option for this often difﬁcult-to-treat older patient
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